Caxton Associates LP boosted its holdings in shares of Inogen, Inc (NASDAQ:INGN) by 4.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,362 shares of the medical technology company’s stock after buying an additional 200 shares during the period. Caxton Associates LP’s holdings in Inogen were worth $416,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of INGN. Ameritas Investment Partners Inc. bought a new stake in Inogen during the first quarter valued at $109,000. Schroder Investment Management Group bought a new stake in Inogen during the second quarter valued at $132,000. Victory Capital Management Inc. boosted its stake in Inogen by 36.1% during the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after buying an additional 459 shares during the period. Sei Investments Co. boosted its stake in Inogen by 38.1% during the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after buying an additional 443 shares during the period. Finally, Jane Street Group LLC bought a new stake in Inogen during the first quarter valued at $203,000.
Shares of Inogen, Inc (NASDAQ:INGN) opened at 94.30 on Friday. Inogen, Inc has a 1-year low of $50.24 and a 1-year high of $105.35. The company’s 50-day moving average price is $98.08 and its 200 day moving average price is $90.65. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 81.86 and a beta of 0.99.
Inogen (NASDAQ:INGN) last released its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The business had revenue of $64.10 million during the quarter, compared to the consensus estimate of $59.99 million. During the same quarter in the prior year, the firm earned $0.25 EPS. The business’s revenue was up 17.4% on a year-over-year basis. On average, analysts predict that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the company. Piper Jaffray Companies reissued a “hold” rating and set a $90.00 price objective on shares of Inogen in a research note on Tuesday, September 12th. Needham & Company LLC reissued a “buy” rating and set a $108.00 price objective on shares of Inogen in a research note on Friday, September 1st. BidaskClub lowered Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, J P Morgan Chase & Co lifted their price objective on Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $90.80.
ILLEGAL ACTIVITY WARNING: This report was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/10/13/inogen-inc-ingn-shares-bought-by-caxton-associates-lp.html.
In other Inogen news, EVP Matt Scribner sold 2,500 shares of the stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $94.21, for a total transaction of $235,525.00. Following the completion of the transaction, the executive vice president now owns 4,833 shares of the company’s stock, valued at approximately $455,316.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Alison Bauerlein sold 6,667 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $92.64, for a total transaction of $617,630.88. Following the transaction, the executive vice president now directly owns 15,000 shares of the company’s stock, valued at approximately $1,389,600. The disclosure for this sale can be found here. Insiders have sold a total of 59,667 shares of company stock valued at $5,725,486 in the last three months. Insiders own 5.31% of the company’s stock.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.